TriN2755

TriN2755 is a synthetic triazene derivative and small molecule alkylating antineoplastic agent developed for intravenous use in cancer therapy. Upon metabolic activation via N-demethylation, TriN2755 is converted into highly reactive carbocations that alkylate DNA and other macromolecules. This leads to DNA cross-linking, inhibition of DNA replication and repair, and ultimately induces apoptosis in tumor cells. The compound exhibits high hydrophilicity, photostability, and a favorable toxicity profile compared to other triazenes. It has been investigated primarily for the treatment of cancers such as melanoma, breast cancer, colon cancer in humans[2][3], as well as histiocytic sarcoma in dogs[4][6]. In preclinical studies and phase I trials (including veterinary studies), the main dose-limiting toxicities were mild gastrointestinal adverse events such as fatigue, nausea, vomiting, anorexia, and diarrhea[4][6]. The drug was developed by Trin Therapeutics.

Other names

triazene derivative trin2755